Menée sur des cellules humaines de cancer du pancréas, cette étude analyse l'effet des radiofréquences sur les mitochondries des cellules tumorales

Noninvasive radiofrequency treatment effect on mitochondria in pancreatic cancer cells

Curley, Steven A. ; Palalon, Flavio ; Lu, Xiaolin ; Koshkina, Nadezhda V.

BACKGROUND : The development of novel therapeutic approaches for cancer therapy is important, especially for tumors that have poor response or develop resistance to standard chemotherapy and radiation. We discovered that noninvasive radiofrequency (RF) fields can affect cancer cells but not normal cells, inhibit progression of tumors in mice, and enhance the anticancer effects of chemotherapy. However, it remains unclear what physiological and molecular mechanisms this treatment induces inside [...]

Cet article passe en revue les avancées récentes en matière de radiothérapie dans le traitement des tumeurs hépatiques primitives

Radiation Therapy for Liver Tumors: Ready for Inclusion in Guidelines?

Tanguturi, Shyam K. ; Wo, Jennifer Y. ; Zhu, Andrew X. ; Dawson, Laura A. ; Hong, Theodore S.

Despite the historically limited role of radiotherapy in the management of primary hepatic malignancies, modern advances in treatment design and delivery have renewed enthusiasm for radiation as a potentially curative treatment modality. Surgical resection and/or liver transplantation are traditionally regarded as the most effective forms of therapy, although the majority of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma present with locally advanced or unresectable [...]

Menée sur 57 patients atteints d'un cancer du poumon non à petites cellules non opérable traité par radiothérapie corporelle stéréotaxique, cette étude évalue l'association entre la dose de rayonnements délivrée au niveau de la région hilaire et le risque de récidive ganglionnaire

Incidental Prophylactic Nodal Irradiation and Patterns of Nodal Relapse in Inoperable Early Stage NSCLC Patients Treated With SBRT: A Case-Matched Analysis

Lao, Louis ; Hope, Andrew J. ; Maganti, Manjula ; Brade, Anthony ; Bezjak, Andrea ; Saibishkumar, Elantholi P. ; Giuliani, Meredith ; Sun, Alexander ; Cho, B. C. John

Purpose : Reported rates of non-small cell lung cancer (NSCLC) nodal failure following stereotactic body radiation therapy (SBRT) are lower than those reported in the surgical series when matched for stage. We hypothesized that this effect was due to incidental prophylactic nodal irradiation. Methods and Materials : A prospectively collected group of medically inoperable early stage NSCLC patients from 2004 to 2010 was used to identify cases with nodal relapses. Controls were matched to cases, [...]

Mené sur 78 patients atteints d'un cancer du poumon non à petites cellules de stade II, IIIA ou IIIB, cet essai multicentrique de phase II évalue, du point de vue de la survie sans progression et de la survie globale à 5 et 10 ans, l'intérêt d'une chimiothérapie néoadjuvante d'induction à base de docétaxel et de cisplatine avant un protocole thérapeutique comportant une intervention chirurgicale ou une chimioradiothérapie par docétaxel puis une chimiothérapie adjuvante avec ce même agent anticancéreux

Multicenter Phase II Study evaluating Docetaxel and Cisplatin as Neoadjuvant Induction Regimen prior to Surgery or Radiochemotherapy with Docetaxel, followed by adjuvant Docetaxel Therapy in chemonaive Patients with NSCLC Stage II, IIIA and IIIB (TAX-AT 1.203 Trial)

Kocher, F. ; Pircher, A. ; Mohn-Staudner, A. ; Romeder, F. ; Duller, W. ; Steinmaurer, M. ; Eckmayr, J. ; Schmid, T. ; Hilbe, W. ; Fiegl, M. ; Greil, R.

Objectives : Neoadjuvant therapy with a platinum based doublet is an option in NSCLC patients with upfront resectable disease. However, the role of neoadjuvant induction in stages IIIA and IIIB and in initially not resectable patients is unclear. Patients and Methods : In this phase II trial, 78 patients with locally advanced NSCLC, of whom 56 were considered not resectable at initial diagnosis, were treated with three neoadjuvant cycles of docetaxel and cisplatin and subjected to radical [...]

Menée sur 483 patients atteints d'un cancer localisé de la prostate, cette étude évalue, du point de vue des taux actuariels de survie sans récidive biochimique, de survie sans métastase et de survie spécifique à 10 ans, l'efficacité d'une prostatectomie radicale assistée par robot

Oncologic Outcomes at 10 Years Following Robotic Radical Prostatectomy

Diaz, Mireya ; Peabody, James O. ; Kapoor, Victor ; Sammon, Jesse ; Rogers, Craig G. ; Stricker, Hans ; Lane, Zhaoli ; Gupta, Nilesh ; Bhandari, Mahendra ; Menon, Mani

Background : Reports on long-term oncologic outcomes for patients who undergo robot-assisted radical prostatectomy (RARP) are scant, as for radical prostatectomy covering only the contemporary prostate-specific antigen (PSA) era. Objective : To evaluate cancer control in men who underwent RARP at least 10 yr ago. Design, setting, and participants : From 2001 to 2003, we followed 483 consecutive men with localized prostate cancer who underwent RARP at a high-volume tertiary center. Intervention [...]

Menée à partir de données portant sur 46 patients atteints d'un sarcome des tissus mous avec métastases pulmonaires et traités entre 2003 et 2013 (durée médiane de suivi : 31,8 mois), cette étude évalue, du point de vue de la survie, l'intérêt d'une métastasectomie pulmonaire

Pulmonary metastasectomy for soft tissue sarcoma – Report from a dual institution experience at the Medical University of Vienna

Schur, S. ; Hoetzenecker, K. ; Lamm, W. ; Koestler, W. J. ; Lang, G. ; Amann, G. ; Funovics, P. ; Nemecek, E. ; Noebauer, I. ; Windhager, R. ; Klepetko, W. ; Brodowicz, T.

Background : Pulmonary metastasectomy when possible has become therapeutic standard in soft tissue sarcoma patients. However, published reports frequently describe mixed series of patients with bone or soft tissue sarcoma. We report the outcome of 46 soft tissue sarcoma (STS) patients who underwent pulmonary metastasectomy (PM). Methods : This current analysis includes retrospective survival data from 46 consecutive STS patients with pulmonary metastases who underwent PM at the Medical [...]

Menée à partir des données des registres américains des cancers portant sur 2 525 patientes atteintes d'un cancer du sein de stade T3N0M0 diagnostiqué entre 2000 et 2010, cette étude évalue, du point de vue de la survie spécifique et de la survie globale, l'intérêt d'une radiothérapie après mastectomie radicale

Postmastectomy radiation therapy for T3N0: A SEER analysis

Johnson, Matthew E. ; Handorf, Elizabeth A. ; Martin, Jeffrey M. ; Hayes, Shelly B.

BACKGROUND : There is conflicting evidence regarding the benefit of postmastectomy radiation therapy (PMRT) for pathologic stage T3N0M0 breast cancers. We analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database to investigate the benefit of PMRT in this patient population. METHODS : We queried the SEER database for T3N0M0 breast cancer patients diagnosed from 2000 to 2010 who underwent modified radical mastectomy. We excluded males, patients with unknown radiation [...]

Mené sur 74 patients atteints d'un carcinome épidermoïde de la tête et du cou de stade III/IV, cet essai de phase II évalue l'efficacité, du point de vue de la survie sans événement et de la survie globale à 3 ans, et la toxicité d'un traitement d'induction par cetuximab-paclitaxel-carboplatine suivi d'une chimioradiothérapie utilisant les mêmes agents anticancéreux

Induction cetuximab, paclitaxel and carboplatin followed by chemoradiation with cetuximab, paclitaxel and carboplatin for stage III/IV head and neck squamous cancer: A Phase II ECOG-ACRIN trial (E2303)

Wanebo, H. J. ; Lee, J. ; Burtness, B. A. ; Ridge, J. A. ; Ghebremichael, M. ; Spencer, S. A. ; Psyrri, D. ; Pectasides, E. ; Rimm, D. ; Rosen, F. R. ; Hancock, M. R. ; Tolba, K. A. ; Forastiere, A. A.

Background : E2303 evaluated cetuximab, paclitaxel and carboplatin used as induction therapy and concomitant with radiation therapy in patients with stage III/IV head and neck squamous cell carcinoma (HNSCC) determining pathologic complete response, event-free survival, and toxicity. Patients and Methods : Patients with resectable stage III/IV HNSCC underwent induction therapy with planned primary site restaging biopsies (at week 8 in clinical complete responders and at week 14 if disease [...]

Cet article passe en revue les perspectives offertes par le développement de peptides bioactifs pour le traitement des cancers

Peptide-based cancer therapy: Opportunity and challenge

Wu, Dongdong ; Gao, Yanfeng ; Qi, Yuanming ; Chen, Lixiang ; Ma, Yuanfang ; Li, Yanzhang

Cancer is one of the leading causes of death worldwide. Conventional cancer therapies mainly focus on mass cell killing without high specificity and often cause severe side effects and toxicities. Peptides are a novel class of anticancer agents that could specifically target cancer cells with lower toxicity to normal tissues, which will offer new opportunities for cancer prevention and treatment. Anticancer peptides face several therapeutic challenges. In this review, we present the sources and [...]

Menée in vivo, cette étude suggère l'intérêt du dipyrimadole, un médicament doté de propriétés anti-agrégantes plaquettaires, en combinaison avec une statine pour le traitement des patients atteints d'un myélome multiple ou d'une leucémie myéloïde aiguë récidivante

Immediate Utility of Two Approved Agents to Target both the Metabolic Mevalonate Pathway and its Restorative Feedback loop

Pandyra, Aleksandra ; Mullen, Peter J ; Kalkat, Manpreet ; Yu, Rosemary ; Pong, Janice T ; Li, Zhihua ; Trudel, Suzanne ; Lang, Karl S ; Minden, Mark D ; Schimmer, Aaron D ; Penn, Linda Z.

New therapies are urgently needed for hematological malignancies especially in relapsed acute myelogenous leukemia (AML) and multiple myeloma (MM) patients. We and others have previously shown that FDA-approved statins, which are used to control hypercholesterolemia and target the mevalonate pathway (MVA), can trigger tumor-selective apoptosis. Our goal was to identify other FDA-approved drugs that synergize with statins to further enhance the anticancer activity of statins in vivo. Using a [...]

Cet article passe en revue les résultats récents d'études cliniques de vaccins thérapeutiques dirigés contre des antigènes associés aux tumeurs

Therapeutic vaccines for cancer: an overview of clinical trials

Melero, Ignacio ; Gaudernack, Gustav ; Gerritsen, Winald ; Huber, Christoph ; Parmiani, Giorgio ; Scholl, Suzy ; Thatcher, Nicholas ; Wagstaff, John ; Zielinski, Christoph ; Faulkner, Ian ; Mellstedt, Hakan

The therapeutic potential of host-specific and tumour-specific immune responses is well recognized and, after many years, active immunotherapies directed at inducing or augmenting these responses are entering clinical practice. Antitumour immunization is a complex, multi-component task, and the optimal combinations of antigens, adjuvants, delivery vehicles and routes of administration are not yet identified. Active immunotherapy must also address the immunosuppressive and tolerogenic mechanisms [...]

Cet article passe en revue les travaux récents sur le développement de traitements anticancéreux à base de virus oncolytiques

Going viral with cancer immunotherapy

Lichty, Brian D. ; Breitbach, Caroline J. ; Stojdl, David F. ; Bell, John C.

Recent clinical data have emphatically shown the capacity of our immune systems to eradicate even advanced cancers. Although oncolytic viruses (OVs) were originally designed to function as tumour-lysing therapeutics, they have now been clinically shown to initiate systemic antitumour immune responses. Cell signalling pathways that are activated and promote the growth of tumour cells also favour the growth and replication of viruses within the cancer. The ability to engineer OVs that express [...]

Menée sur des lignées cellulaires de lymphome, de leucémie et de myélome multiple, des échantillons prélevés sur des patients atteints d'un myélome multiple et à l'aide de xénogreffes, cette étude évalue l'activité antitumorale d'un anticorps anti CD38 appelé SAR650984

SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent anti-tumor activity in models of multiple myeloma and other CD38+ hematologic malignancies

Deckert, Jutta ; Wetzel, Marie-Cecile ; Bartle, Laura M ; Skaletskaya, Anna ; Goldmacher, Victor ; Vallee, Francois ; Zhou-Liu, Qing ; Ferrari, Paul ; Pouzieux, Stephanie ; Lahoute, Charlotte ; Dumontet, Charles ; Plesa, Adriana ; Chiron, Marielle ; Lejeune, Pascale ; Chittenden, Thomas ; Park, Peter U ; Blanc, Veronique

Purpose: The CD38 cell surface antigen is expressed in diverse hematologic malignancies including multiple myeloma (MM), B-cell non-Hodgkin lymphoma (NHL), B-cell chronic lymphocytic leukemia (B-CLL), B-cell acute lymphoblastic leukemia (ALL) and T-cell ALL. Here we assessed the anti-tumor activity of the anti-CD38 antibody SAR650984. Experimental Design: Activity of SAR650984 was examined on lymphoma, leukemia and MM cell lines, primary MM samples and MM xenograft models in immunodeficient [...]

Menée à l'aide d'un modèle murin de leucémie myéloïde aiguë récidivante, cette étude suggère l'intérêt de l'echinomycine, un inhibiteur de HIF1 alpha, pour éradiquer les cellules souches leucémiques

Preclinical evaluation of Echinomycin: therapeutic efficacy in relapsed acute myeloid leukemia without adverse effects on host hematopoietic stem cells

Wang, Yin ; Liu, Yan ; Tang, Fei ; Bernot, Kelsie M. ; Schore, Reuven ; Marcucci, Guido ; Caligiuri, Michael A. ; Zheng, Pan ; Liu, Yang

Acute myeloid leukemia (AML) often relapses following chemotherapy-induced remission and is generally chemo-resistant. Given the potential role for cancer stem cells in relapse, targeting of the leukemia initiating cell (LIC) in AML may provide improved outcome following remission induction. However, due to overlap in their self-renewal program with normal hematopoietic stem cells (HSCs), therapeutic targeting of the LIC may have an adverse effect on long-term hematopoietic recovery. Here we [...]

Menée in vitro et in vivo, cette étude évalue l'activité antitumorale d'un inhibiteur de la protéine kinase C-bêta, appelé AEB071, pour le traitement d'une leucémie lymphocytaire chronique

PKC-bêta as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates pre-clinical activity in CLL

El-Gamal, Dalia ; Williams, Katie ; LaFollette, Taylor ; Cannon, Matthew ; Blachly, James S. ; Zhong, Yiming ; Woyach, Jennifer ; Williams, Erich ; Awan, Farrukh ; Jones, Jeffrey ; Andritsos, Leslie ; Maddocks, Kami ; Wu, Chia-Hsien ; Chen, Ching-Shih ; Lehman, Amy ; Zhang, Xiaoli ; Lapalombella, Rosa ; Byrd, John C.

Targeting B-cell receptor (BCR) signaling in chronic lymphocytic leukemia has been successful with durable remissions observed with several targeted therapeutics. Protein Kinase C-β (PKC-β) is immediately downstream of BCR and has been shown to be essential to CLL cell survival and proliferation in vivo. We therefore evaluated sotrastaurin (AEB071), an orally administered potent PKC inhibitor, on CLL cell survival both in vitro and in vivo. AEB071 shows selective cytotoxicity against B-CLL [...]

Cet article passe en revue les enjeux associés à l'identification des patients atteints d'un mélanome et susceptibles de bénéficier d'une survie à long terme grâce à une immunothérapie, notamment l'ipilimumab

Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma

McDermott, David ; Lebbé, Celeste ; Stephen Hodi, F. ; Maio, Michele ; Weber, Jeffrey S. ; Wolchok, Jedd D. ; Thompson, John A. ; Balch, Charles M.

Historically, the median overall survival for patients with stage IV melanoma was less than 1 year and the 5-year survival rate was ∼10%. Recent advances in therapy have raised 5-year survival expectations to ∼20%. Notably, a subset of melanoma patients who receive immunotherapy with high-dose interleukin-2, and now ipilimumab, can achieve long-term survival of at least 5 years. A major goal in melanoma research is to increase the number of patients who experience this overall survival benefit. [...]

Menée sur des lignées cellulaires, sur des échantillons prélevés sur des patients atteints d'un myélome multiple et à l'aide de xénogreffes, cette étude française évalue l'activité antitumorale d'une molécule appelée PRIMA-1Met

PRIMA-1Met induces myeloma cell death independently of p53 by impairing the GSH/ROS balance

Tessoulin, Benoît ; Descamps, Géraldine ; Moreau, Philippe ; Maïga, Sophie ; Lodé, Laurence ; Godon, Catherine ; Marionneau-Lambot, Séverine ; Oullier, Thibauld ; Le Gouill, Steven ; Amiot, Martine ; Pellat-Deceunynck, Catherine

The aim of this study was to assess the efficiency of PRIMA-1Met in inducing myeloma cell death using 27 human myeloma cell lines (HMCLs) and 23 primary samples. Measuring the LD50 of HMCLs revealed that HMCLs displayed heterogeneous sensitivity, with an LD50 ranging from 4 µM to more than 200 µM. The sensitivity of HMCLs did not correlate with myeloma genomic heterogeneity or TP53 status, and PRIMA-1Met did not induce or increase expression of the p53 target genes CDKN1A or TNFRSF10B/DR5. [...]

Cet article passe en revue les travaux récents sur le développement de thérapies ciblant la voie de signalisation PI3K/AKT/mTOR pour le traitement des patients atteints d'un carcinome épidermoïde du poumon

Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin(mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma

Beck, Joseph Thaddeus ; Ismail, Amen ; Tolomeo, Christina

Squamous cell lung carcinoma accounts for approximately 30% of all non-small cell lung cancers (NSCLCs). Despite progress in the understanding of the biology of cancer, cytotoxic chemotherapy remains the standard of care for patients with squamous cell lung carcinoma, but the prognosis is generally poor. The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is one of the most commonly activated signaling pathways in cancer, leading to cell proliferation, [...]

Menée sur des lignées cellulaires et à l'aide de xénogreffes, cette étude suggère l'intérêt d'un traitement combinant un inhibiteur de PI3K, appelé BYL719, et un inhibiteur de CDK 4/6 pour le traitement d'un cancer du sein présentant des mutations du gène PI3K

CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors

Vora, Sadhna R ; Juric, Dejan ; Kim, Nayoon ; Mino-Kenudson, Mari ; Huynh, Tiffany ; Costa, Carlotta ; Lockerman, Elizabeth L ; Pollack, Sarah F ; Liu, Manway ; Li, Xiaoyan ; Lehar, Joseph ; Wiesmann, Marion ; Wartmann, Markus ; Chen, Yan ; Cao, Z.  Alexander ; Pinzon-Ortiz, Maria ; Kim, Sunkyu ; Schlegel, Robert ; Huang, Alan ; Engelman, Jeffrey A

Activation of the phosphoinositide 3-kinase (PI3K) pathway occurs frequently in breast cancer. However, clinical results of single-agent PI3K inhibitors have been modest to date. A combinatorial drug screen on multiple PIK3CA mutant cancers with decreased sensitivity to PI3K inhibitors revealed that combined CDK 4/6-PI3K inhibition synergistically reduces cell viability. Laboratory studies revealed that sensitive cancers suppress RB phosphorylation upon treatment with single-agent PI3K [...]

Menée in vitro et in vivo, cette étude évalue l'activité antitumorale d'un anticorps bispécifique ciblant deux épitopes sur le récepteur HER2, appelé COVA208, pour le traitement des cancers du sein HER2+

A Bispecific HER2 Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action

Brack, Simon ; Attinger-Toller, Isabella ; Schade, Babette ; Mourlane, Frédéric ; Klupsch, Kristina ; Woods, Richard ; Hachemi, Helen ; von der Bey, Ulrike ; König-Friedrich, Susann ; Bertschinger, Julian ; Grabulovski, Dragan

Upregulation of HER2 is a hallmark of 20% to 30% of invasive breast cancers, rendering this receptor an attractive target for cancer therapy. Although HER2 targeting agents have provided substantial clinical benefit as cancer therapeutics, there is a need for the development of new agents aiming at circumventing anti-HER2 resistance. Based on the approved antibody pertuzumab we have created a panel of bispecific FynomAbs which target two epitopes on HER2. FynomAbs are fusion proteins of an [...]

Menée in vitro et in vivo, cette étude suggère l'intérêt d'un anticorps appelé BCMab1 pour le traitement d'un cancer de la vessie

BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo

Li, Chong ; Yang, Zhao ; Du, Ying ; Tang, Haidong ; Chen, Jun ; Hu, Deqing ; Fan, Zusen

Purpose: To identify a novel biomarker for bladder cancer targeting therapy. Experimental Design: The human bladder cancer cell line T24 cells were used as immunogen to generate mouse monoclonal antibodies. We screened and identified a specific antibody BCMab1 against bladder cancer. We examined BCMab1 antigen expression in the patients with bladder cancer through immunohistochemical staining and investigated the BCMab1 antigen association with clinical severity. We detected the antitumor [...]

Mené sur 19 patients atteints d'une tumeur solide de stade avancé, cet essai de phase I évalue la dose recommandée et l'activité antitumorale d'un traitement combinant sirolimus et gemcitabine

Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours

Martin-Liberal, J. ; Gil-Martin, M. ; Sainz-Jaspeado, M. ; Gonzalo, N. ; Rigo, R. ; Colom, H. ; Munoz, C. ; Tirado, O. M. ; Garcia del Muro, X.

Background: We conducted a phase I study in patients with advanced solid tumours to identify the recommended dose, assess pharmacokinetics (PK), pharmacodynamic activity and preclinical antitumour efficacy of the combination of sirolimus and gemcitabine. Methods: Nineteen patients were treated with sirolimus 2 or 5 mg daily and gemcitabine 800 or 1000 mg m−2 on days 1 and 8. Dose escalation depended on dose-limiting toxicity (DLT) rate during the first 3-week period. Paired skin biopsies were [...]

Menée sur 145 patients atteints d'une forme de leucémie myéloïde aiguë (CBF-AML), cette étude rétrospective française évalue l'efficacité du gemtuzumab ozogamicine en traitement de sauvetage

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup

Hospital, Marie-Anne ; Prebet, Thomas ; Bertoli, Sarah ; Thomas, Xavier ; Tavernier, Emmanuelle ; Braun, Thorsten ; Pautas, Cécile ; Perrot, Aurore ; Lioure, Bruno ; Rousselot, Philippe ; Tamburini, Jérôme ; Cluzeau, Thomas ; Konopacki, Johanna ; Randriamalala, Edouard ; Berthon, Céline ; Gourin, Marie-Pierre ; Recher, Christian ; Cahn, Jean-Yves ; Ifrah, Norbert ; Dombret, Hervé ; Boissel, Nicolas

Although CBF-AML (t(8;21) or inv(16)/t(16;16)) represents a favorable cytogenetic AML subgroup, 30-40% of these patients relapse after standard intensive chemotherapy. The encouraging results of GO in newly diagnosed AML and particularly in CBF-AML incited us to retrospectively investigate the impact of GO-based salvage in these patients. We retrospectively analysed the outcome of 145 patients with CBF-AML (59 t(8;21), 86 inv(16)/t(16;16)) in first relapse. As salvage, 48 patients received [...]

Mené sur 87 patients atteints d'une leucémie myéloïde aiguë (âge médian: 75 ans), cet essai de phase II évalue l'efficacite et la toxicité de l'ajout de volasertib à une chimiothérapie par cytarabine à faible dose

Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy

Döhner, Hartmut ; Lübbert, Michael ; Fiedler, Walter ; Fouillard, Loic ; Haaland, Alf ; Brandwein, Joseph M. ; Lepretre, Stephane ; Reman, Oumedaly ; Turlure, Pascal ; Ottmann, Oliver G. ; Müller-Tidow, Carsten ; Krämer, Alwin ; Raffoux, Emmanuel ; Döhner, Konstanze ; Schlenk, Richard F. ; Voss, Florian ; Taube, Tillmann ; Fritsch, Holger ; Maertens, Johan

Treatment outcomes for older patients with acute myeloid leukemia (AML) have remained dismal. This randomized, phase 2 trial in AML patients not considered suitable for intensive induction therapy compared low-dose cytarabine (LDAC) with or without volasertib, a highly potent and selective inhibitor of polo-like kinases. Eighty-seven patients (median age 75 years) received LDAC 20 mg b.i.d. subcutaneously days 1-10 or LDAC + volasertib 350 mg intravenously days 1 + 15, every 4 weeks. Response [...]

Menée sur 189 patients atteints d'un cancer du poumon à petites cellules réfractaire ou non aux sels de platine, cet essai de phase II évalue l'efficacité, du point de vue de la survie sans progression à 3 mois, et la toxicité de l'ajout de ziv-aflibercept au topotecan

Southwest Oncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Cancer

Allen, Jeffrey W. ; Moon, James ; Redman, Mary ; Gadgeel, Shirish M. ; Kelly, Karen ; Mack, Philip C. ; Saba, Hanna M. ; Mohamed, Mohamed K. ; Jahanzeb, Mohammad ; Gandara, David R.

Purpose : Development of new therapies for previously treated small-cell lung cancer (SCLC) is a major unmet need. Here, we describe a randomized, phase II trial of weekly topotecan with or without ziv-aflibercept (VEGF-trap) in this clinical setting. Patients and Methods : Patients with previously treated SCLC (one line of platinum-based chemotherapy), performance status of 0 to 1, adequate organ function, treated brain metastases, and no recent vascular events or bleeding diatheses were [...]

Mené sur 79 patientes atteintes d'un cancer métastatique du sein triplement négatif, cet essai de phase II évalue la faisabilité, l'efficacité et la toxicité d'un vaccin peptidique personnalisé

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

Takahashi, Ryuji ; Toh, Uhi ; Iwakuma, Nobutaka ; Takenaka, Miki ; Otsuka, Hiroko ; Furukawa, Mina ; Fujii, Teruhiko ; Seki, Naoko ; Kawahara, Akihiko ; Kage, Masayoshi ; Matsueda, Satoko ; Akagi, Yoshito ; Yamada, Akira ; Itoh, Kyogo ; Sasada, Tetsuro

INTRODUCTION:Since treatment modalities for metastatic recurrent triple-negative breast cancer (mrTNBC) are limited, a novel treatment approach including immunotherapy is required. We have developed a novel regimen of personalized peptide vaccination (PPV), in which vaccine antigens are individually selected from a pool of different peptide candidates based on the pre-existing host immunity. Herein we conducted a phase II study of PPV for metastatic recurrent breast cancer patients to [...]

Cet article présente les recommandations de trois sociétés savantes européennes sur le diagnostic et le traitement d'un cancer anal ainsi que le suivi des patients

Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Glynne-Jones, R. ; Nilsson, P. J. ; Aschele, C. ; Goh, V. ; Peiffert, D. ; Cervantes, A. ; Arnold, D.

These Guidelines were developed by the European Society for Medical Oncology (ESMO), the European Society of Surgical Oncology (ESSO) and the European Society of Radiotherapy and Oncology (ESTRO) and are published jointly in the Annals of Oncology, the European Journal of Surgical Oncology and Radiotherapy & Oncology. The three societies nominated authors to write the guidelines as well as reviewers to comment on them. aetiology : Squamous cell carcinoma of the anus (SCCA) is strongly [...]

Menée sur 201 patients atteints d'un cancer du poumon non à petites cellules de stade IV, cette étude chinoise évalue, en fonction de la dose de rayonnements délivrée et du point de vue des taux de survie sans progression loco-régionale et de survie globale à 1, 2, 3 et 5 ans, l'efficacité d'une radiothérapie thoracique tridimensionnelle en combinaison avec une chimiothérapie concomitante

Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study

Ouyang, Wei-Wei ; Su, Sheng-Fa ; Hu, Yin-Xiang ; Lu, Bing ; Ma, Zhu ; Li, Qing-Song ; Li, Hui-Qin ; Geng, Yi-Chao

Background : The objective of this study was to evaluate the radiation dose and response in terms of local-regional progression-free survival (LRPFS) and overall survival (OS) of patients with stage IV non-small cell lung cancer (NSCLC) undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy. Methods : In all, we enrolled 201 patients with stage IV NSCLC in this study and analyzed OS in 159 patients and LRPFS in 120. Results : The 1-, 2-, 3-, and 5-year OS rates were [...]

Menée à partir de données portant sur 171 patients atteints d'un chondrosarcome avancé non résécable, diagnostiqué entre 1980 et 2011, cette étude multicentrique italo-néerlandaise évalue les taux de survie globale à 2, 4 et 5 ans, puis évalue le bénéfice en termes de survie d'une chimiothérapie à base de doxorubicine, d'un traitement par imatinib et sirolimus ou d'une radiothérapie

Outcome of advanced, unresectable conventional central chondrosarcoma

van Maldegem, Annemiek M. ; Gelderblom, Hans ; Palmerini, Emanuela ; Dijkstra, Sander D. ; Gambarotti, Marco ; Ruggieri, Pietro ; Nout, Remi A. ; van de Sande, Michiel A. J. ; Ferrari, Cristina ; Ferrari, Stefano ; Bovée, Judith V. M. G. ; Picci, Piero

BACKGROUND : For patients who have chondrosarcoma with unresectable disease, because of tumor location, tumor size, or extensive metastatic disease, treatment options are very limited because of their relative resistance to radiotherapy and chemotherapy. The overall survival of this patient population is poor; however, specific studies are lacking, and large series have not been published. Therefore, the authors conducted this retrospective, 2-center study to gain insight into the outcome of [...]

Menée à l'aide d'un modèle numérique et de données empiriques, cette étude met en évidence l'importance de prendre en compte l'hétérogénéité intratumorale pour déterminer la combinaison de médicaments la plus efficace

Intratumor heterogeneity alters most effective drugs in designed combinations

Zhao, Boyang ; Hemann, Michael T. ; Lauffenburger, Douglas A.

The substantial spatial and temporal heterogeneity observed in patient tumors poses considerable challenges for the design of effective drug combinations with predictable outcomes. Currently, the implications of tissue heterogeneity and sampling bias during diagnosis are unclear for selection and subsequent performance of potential combination therapies. Here, we apply a multiobjective computational optimization approach integrated with empirical information on efficacy and toxicity for [...]